All In Biotech

Drug Trial Radar · NCT07046494

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

253

Actual

Start

Jul 25, 2025

Primary completion

Aug 5, 2026

Study completion Sep 24, 2026

Sponsor

Lead sponsor
Rapport Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.

Conditions

  • Bipolar 1 Disorder

Interventions

  • RAP-219Drug

    RAP-219 tablets administered orally, once daily for 21 days

  • PlaceboOther

    Matching placebo tablets administered orally, once daily for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Young Mania Rating Scale (YMRS)Time frame: Baseline to End of Treatment at Week 3

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research - Little Rock

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • Inland Psychiatric Medical Group - Chino

    Chino, California

  • Synergy Clinical Research Center - San Diego

    Lemon Grove, California

  • Collaborative Neuroscience Research - Los Alamitos

    Los Alamitos, California

  • NRC Research Institute - Orange

    Orange, California

  • NeuroBehavioral Hospitals of the Palm Beaches - South

    Boynton Beach, Florida

  • United Research Institute

    Hialeah, Florida

  • CenExel - Hollywood

    Hollywood, Florida

  • Segal Trials - Miami Lakes Medical Research Early Phase, Inpatient & Outpatient Site

    Miami Lakes, Florida

  • Neuroscience Research Institute at Ambrosia

    West Palm Beach, Florida

  • CenExel - Decatur

    Decatur, Georgia

  • Pillar Clinical Research - Chicago

    Chicago, Illinois

  • CenExel - Gaithersburg

    Gaithersburg, Maryland

  • Arch Clinical Trials

    St Louis, Missouri

  • Richmond Behavioral Associates

    Staten Island, New York

  • New Hope Clinical Research

    Charlotte, North Carolina

  • Community Clinical Research, Inc.

    Austin, Texas

  • HD Research - Memorial Hermann Village

    Houston, Texas

  • Pillar Clinical Research - Richardson

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.